On May 13, 2026, Armata Pharmaceuticals, Inc. (the “Company”) announced in the press release furnished hereto as Exhibit 99.1 that, on May 12, 2026, it had entered into, as borrower, a credit and sec…
The Company will be obligated to make an additional fixed royalty payment upon achieving specified sales milestones. The Company may also be obligated to make a payment to CFF if the Company transfer…
we received the convertible loan (the "Convertible Loan") in the aggregate amount of $30.0 million from Innoviva Sub pursuant to the secured convertible credit and security agreement
The MTEC Agreement specifies that the award will be paid to the Company over the term of the award through a cost reimbursable model, based on agreed upon cost share percentages, and the money receiv…
The Company recognized $ 0.8 million and $ 0.5 million in grant and award revenue from the MTEC Agreement during the three months ended March 31, 2026 and 2025, respectively.
Armata Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ARMP-DEBT
Debt stack $373.7M
90%
Market cache reports total debt of $373.7M.
ARMP-DEBT-7850
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2023-12-31.
ARMP-DEBT-7849
Warrants outstanding: 393939
90%
xbrl warrant detail from xbrl 2020-12-31.
Armata Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Armata Pharmaceuticals, Inc..
Armata Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
ARMP-OWNER-MADISON-ASSET-MANAGEMENT-LLC
Madison Asset Management, LLC
90%
13F overlay lists Madison Asset Management, LLC as top holder; 45 tracked holders.
Armata Pharmaceuticals, Inc. Extended Supply Chain Network
